Rallybio Corp financial data

Symbol
RLYB on Nasdaq
Industry
Pharmaceutical Preparations
Location
234 Church Street, Suite 1020, New Haven, Connecticut
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Rallybio Holdings, LLC (to 6/7/2021)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.34 K % -24.2%
Debt-to-equity 8.2 % +31.4%
Return On Equity -43.6 %
Return On Assets -61.5 % -42.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8 M shares -0.69%
Common Stock, Shares, Outstanding 37.8 M shares +0.17%
Entity Public Float 134 M USD +11.4%
Common Stock, Value, Issued 4 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 40.8 M shares +1.3%
Weighted Average Number of Shares Outstanding, Diluted 40.8 M shares +1.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 55.3 M USD +24.9%
General and Administrative Expense 25.1 M USD -9.5%
Operating Income (Loss) -80.3 M USD -11.7%
Nonoperating Income (Expense) 6.23 M USD +67.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -65.6 M USD -44.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -76.3 M USD -9.79%
Earnings Per Share, Basic -1.88 USD/shares +7.84%
Earnings Per Share, Diluted -1.88 USD/shares +7.84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.3 M USD -51.2%
Marketable Securities, Current 74.9 M USD -32.5%
Cash, Cash Equivalents, and Short-term Investments 94.2 M USD -37.4%
Other Assets, Current 768 K USD -27.7%
Assets, Current 98.5 M USD -38.9%
Property, Plant and Equipment, Net 211 K USD -39%
Operating Lease, Right-of-Use Asset 299 K USD -37.6%
Assets 99.4 M USD -38.8%
Accounts Payable, Current 470 K USD -39.9%
Accrued Liabilities, Current 9.39 M USD +61.4%
Liabilities, Current 10.1 M USD +48.3%
Operating Lease, Liability, Noncurrent 116 K USD -63.9%
Liabilities 10.2 M USD +43.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -71 K USD -16.4%
Retained Earnings (Accumulated Deficit) -254 M USD -42.9%
Stockholders' Equity Attributable to Parent 89.2 M USD -42.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 169 M USD -3.58%
Liabilities and Equity 99.4 M USD -38.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.5 M USD +17.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 10.3 M USD +601%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 37.8 M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.19 M USD +70.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.3 M USD -51.2%
Deferred Tax Assets, Valuation Allowance 78.3 M USD +55.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 78.3 M USD +55.9%
Operating Lease, Liability 392 K USD -29.4%
Depreciation 100 K USD -50%
Payments to Acquire Property, Plant, and Equipment 12 K USD -77.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -76.3 M USD -9.9%
Lessee, Operating Lease, Liability, to be Paid 406 K USD -30.7%
Operating Lease, Liability, Current 223 K USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 176 K USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 230 K USD +15%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14 K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 37.2 M USD +40.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 156 K USD
Additional Paid in Capital 343 M USD +3.07%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 9.96 M USD -5.02%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%